Concepts (81)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 10 | 2021 | 997 | 2.440 |
Why?
|
| Symptom Flare Up | 2 | 2021 | 7 | 0.720 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 468 | 0.630 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 151 | 0.630 |
Why?
|
| Biomarkers | 2 | 2021 | 787 | 0.550 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2018 | 42 | 0.550 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 153 | 0.510 |
Why?
|
| Heart | 1 | 2016 | 232 | 0.440 |
Why?
|
| Heart Rate | 1 | 2016 | 382 | 0.440 |
Why?
|
| Endpoint Determination | 1 | 2013 | 18 | 0.400 |
Why?
|
| Still's Disease, Adult-Onset | 1 | 2011 | 2 | 0.360 |
Why?
|
| Fasciitis | 1 | 2011 | 4 | 0.360 |
Why?
|
| Clarithromycin | 1 | 2011 | 7 | 0.360 |
Why?
|
| Panniculitis | 1 | 2011 | 4 | 0.350 |
Why?
|
| Immunotherapy | 1 | 2013 | 171 | 0.350 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 136 | 0.310 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 251 | 0.310 |
Why?
|
| Humans | 12 | 2021 | 29078 | 0.270 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 538 | 0.260 |
Why?
|
| Cytokines | 2 | 2021 | 456 | 0.250 |
Why?
|
| Disease Progression | 2 | 2021 | 481 | 0.230 |
Why?
|
| Prognosis | 2 | 2021 | 815 | 0.220 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2021 | 75 | 0.200 |
Why?
|
| Withholding Treatment | 2 | 2019 | 20 | 0.170 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 788 | 0.170 |
Why?
|
| Cost of Illness | 1 | 2021 | 54 | 0.160 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 74 | 0.160 |
Why?
|
| Antirheumatic Agents | 1 | 2021 | 57 | 0.160 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 221 | 0.160 |
Why?
|
| Disease Management | 1 | 2021 | 91 | 0.160 |
Why?
|
| Interferon-alpha | 1 | 2019 | 50 | 0.150 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 169 | 0.150 |
Why?
|
| Immunologic Factors | 1 | 2019 | 50 | 0.150 |
Why?
|
| Patient Participation | 1 | 2020 | 58 | 0.150 |
Why?
|
| Prevalence | 1 | 2021 | 523 | 0.150 |
Why?
|
| Middle Aged | 5 | 2020 | 7458 | 0.140 |
Why?
|
| Decision Making | 1 | 2020 | 179 | 0.140 |
Why?
|
| Adult | 5 | 2020 | 8080 | 0.140 |
Why?
|
| Treatment Outcome | 2 | 2021 | 2430 | 0.130 |
Why?
|
| Precision Medicine | 1 | 2018 | 82 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 312 | 0.130 |
Why?
|
| Steroids | 1 | 2017 | 58 | 0.130 |
Why?
|
| Oklahoma | 2 | 2020 | 1062 | 0.110 |
Why?
|
| Electrocardiography | 1 | 2016 | 398 | 0.110 |
Why?
|
| Male | 5 | 2020 | 14049 | 0.110 |
Why?
|
| Prednisone | 1 | 2014 | 54 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2016 | 902 | 0.100 |
Why?
|
| Glucocorticoids | 1 | 2014 | 115 | 0.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 79 | 0.100 |
Why?
|
| Female | 5 | 2020 | 15740 | 0.100 |
Why?
|
| Adaptive Immunity | 1 | 2013 | 38 | 0.100 |
Why?
|
| Interferons | 1 | 2013 | 70 | 0.100 |
Why?
|
| Recurrence | 1 | 2014 | 328 | 0.100 |
Why?
|
| Disability Evaluation | 1 | 2013 | 54 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 612 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 431 | 0.090 |
Why?
|
| Health Status | 1 | 2013 | 149 | 0.090 |
Why?
|
| Respiratory Tract Infections | 1 | 2011 | 37 | 0.090 |
Why?
|
| Immunity, Innate | 1 | 2013 | 233 | 0.090 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2011 | 6 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 379 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 843 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2013 | 1482 | 0.060 |
Why?
|
| Young Adult | 1 | 2011 | 2855 | 0.050 |
Why?
|
| Altruism | 1 | 2020 | 8 | 0.040 |
Why?
|
| Culture | 1 | 2020 | 27 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2019 | 22 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 105 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 92 | 0.040 |
Why?
|
| Minority Groups | 1 | 2020 | 76 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2019 | 426 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2020 | 208 | 0.040 |
Why?
|
| B-Cell Activating Factor | 1 | 2017 | 32 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2017 | 33 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2017 | 56 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2019 | 486 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2017 | 668 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2017 | 1286 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 1009 | 0.030 |
Why?
|
| Time Factors | 1 | 2017 | 1619 | 0.020 |
Why?
|
| Aged | 1 | 2020 | 5627 | 0.020 |
Why?
|